| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-1384SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-25156SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-92711SS | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alexa Fluor 350 | FAB8304U-100UG | |||
| Alexa Fluor 405 | FAB8304V-100UG | |||
| Alexa Fluor 488 | FAB8304G-100UG | |||
| Alexa Fluor 532 | FAB8304X-100UG | |||
| Alexa Fluor 594 | FAB8304T-100UG | |||
| Alexa Fluor 647 | FAB8304R-100UG | |||
| Alexa Fluor 700 | FAB8304N-100UG | |||
| Alexa Fluor 750 | FAB8304S-100UG | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB8304-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP3-43783 | |||
| BSA Free | NBP2-61417-25ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP3-05552-50ul | |||
![Western blot analysis of whole brain tissue lysates using chicken pAb to microtubule associated protein 2 (MAP2), NB300-213, dilution 1:50,000 in green: [1] protein standard (red), [2] adult rat brain, [3] embryonic E20 rat brain, [4] adult mouse brain. Strong band observed at ~280 kDa mark corresponds to two major isoforms of MAP2 protein referred to as MAP2A and MAP2B. Smaller fragments of these isoforms are also detected if the antibody is used at higher concentrations.](http://images.novusbio.com/fullsize/MAP2-Antibody-Western-Blot-NB300-213-img0005.jpg)
![Immunocytochemistry/ Immunofluorescence: MAP2 Antibody [NB300-213] - SUMO1 conjugates are not localized to amyloid plaques. (a) Sagittal brain sections of 24‐week‐old KI/AD & WT/AD animals were stained using anti‐HA antibodies (red), 6E10 antibodies (green) that label amyloid beta 1–42 among other amyloid beta variants (epitope lies within amino acids 3–8 of amyloid beta) & anti‐MAP2 antibodies (blue). Sections of the hippocampal subiculum are shown. Images are representatives of three independent experiments. Scale bar, 25 μm. (b) Anti‐HA signal intensity in amyloid plaques & in cell nuclei was quantified using ImageJ (N = 3, ***significance between WT/AD & KI/AD, p = .0007 in Student's t test) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29633471), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-213_chicken-map2-pab-310202415392532.jpg)
![Immunocytochemistry/ Immunofluorescence: MAP2 Antibody [NB300-213] - Oxytocin receptors (Oxtr) are expressed in mouse hippocampus.(a & b) Coronal sections of the hippocampus (a) & striatum (b) from OxtrVn/+ & Oxtr+/+ mice stained for Venus & DAPI (ac, anterior commisure; cx, cortex; hip, hippocampus; str, striatum). (c) Confocal images of rostral Oxtr+/+ & OxtrVn/+ brain sections including hippocampus, double-labeled for Venus (green) & NeuN (red). (d) Confocal images of Oxtr-expressing neurons in the CA1 subfields of the medial & caudal hippocampus from OxtrVn/+ sections, triple stained with antibodies directed against NeuN (red), MAP2 (magenta), & Venus (green). (e) Representative images of hippocampal mass cultures obtained from OxtrVn/+ mice at P0 mice & processed for immunofluorescence staining at 5, 10, & 14 DIV using antibodies to Venus (green) & GAD67 (red), & DAPI (blue). (f) Quantitative analysis of Venus-positive neurons with (GAD67+) & without colabeling for GAD67 (GAD67-) in hippocampal mass cultures obtained from OxtrVn/+ mice at P0 mice & processed for immunofluorescence staining at 5, 10, & 14 DIV. Data are shown as mean ± SEM.DOI://dx.doi.org/10.7554/eLife.22466.015 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28231043), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-213_chicken-map2-pab-310202416212347.jpg)
![Immunocytochemistry/ Immunofluorescence: MAP2 Antibody [NB300-213] - SUMO1 conjugates remain nuclear during increased amyloid burden. (a) Western blot analysis of subcellular fractions of 36‐week‐old KI/WT & KI/AD mouse brain using anti‐HA antibody (upper two panels) & antibodies to GluN1 (a marker of the postsynaptic compartment) & Synaptophysin (a marker of the presynaptic compartment) to validate the fractionation procedure (lower two panels). H, homogenate; P1, nuclear pellet; S1, supernatant after P1 sedimentation; P2, crude synaptosomal pellet; S2, supernatant after P2 sedimentation; LP1, lysed synaptosomal membranes; LS1, supernatant after LP1 sedimentation; LP2, pellet after LS1 sedimentation, SPM, synaptic plasma membranes. Bracket indicates the anti‐HA signal representing SUMOylation, arrow indicates RanGAP1, stars indicate nonspecific signal detected by the anti‐HA antibody. (b) Brain sagittal sections of aged (36 weeks old) KI/AD (left panels) & WT/AD (right panels) mice were immunostained using antibodies directed against HA (red, labels HA‐HA conjugates), MAP2 (green, labels neuronal somata & dendrites), & Synapsin1 (Syn1, magenta, labels synapses). The images show triple‐labeled neurons of hippocampal subiculum (b), cortical layer 5 (c), & proximal apical dendrite from hippocampal CA3 (d). The white line shows the orientation of the line‐scan used to generate the image stack shown in the bottom side view. Scale bar: 10 μm. Note that the anti‐HA immunosignal is mainly located in neuronal nuclei, only background staining is observed in WT/AD mice. Little anti‐HA signal is observed along MAP2‐positive structures & does not colocalize with Synapsin1 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29633471), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-213_chicken-map2-pab-310202416212317.jpg)
![Immunocytochemistry/ Immunofluorescence: MAP2 Antibody [NB300-213] - Validation of the CRISPR/Cas9 Alsin-/- cells in iPSC, NPC & iPSC-sMN.(A) Electrophoresis result of the PCR reaction using primers flanking exon three & within exon 3. Homozygous deletion was confirmed by the absence of a 2.8 kb. (B) Protein lysates from WT KOLF & Alsin-/- iPSC were loaded onto SDS-PAGE & immunoblotted with Alsin antibody. A band detected at ~184 kDa, but absent in Alsin-/-, corresponds to full-length Alsin. (C) WT KOLF, Alsin-/- iPSC, & neuroprogenitor cells (NPC) were immunostained with pluripotency markers Oct4 & Lin28, & neuroprogenitor markers Sox2 & Pax6, respectively. (D–E) WT KOLF & Alsin-/- iPSC-sMN were immunostained with motor neuron markers such as ChAT, HB9, & ISL1, nuclear dye DAPI, & cytoskeletal marker MAP2. (F) WT KOLF & Alsin-/- iPSC-sMN were immunostained with antibodies against Rab5 & Alsin, along with DAPI (nuclear) & phalloidin (actin) stains. Scale bars, 10 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29469808), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-213_chicken-map2-pab-310202416203714.jpg)
![Immunocytochemistry/ Immunofluorescence: MAP2 Antibody [NB300-213] - PEA decreases astrocyte activation in organotypic cultures of rat hippocampi & rescues neuronal CA3 damage caused by A beta challenge. A beta -challenged (1 μg/ml) slices of rat hippocampi treated for 24 hours w/ PEA (0.1 μM) in presence of selective PPAR gamma antagonist (GW9662, 9 nM) or selective PPAR alpha antagonist (MK886, 3 μM). (A) Nissl staining showing effect of treatment on morphology of organotypic hippocampal slices. Scale bar: 80 μm. A beta caused a marked neuronal loss, mainly in CA3 region of hippocampus, as highlighted by arrows. PEA able to reverse this effect. (B) Representative photomicrographs of CA3 region showing Results of immunofluorescence experiments aimed at investigating effect of treatments on astrocyte activation & neuronal loss, as determined by immunostaining for GFAP (green) & MAP2 (red) alone or merged, respectively. Nuclei stained w/ Hoechst (blue). Scale bar: 10 μm. Arrows in photomicrographs indicate astrocyte infiltration events & apoptotic condensation in nuclei of adjacent neurons. (C) Relative quantification of GFAP-positive cell number as a count of astrocyte proliferation. (D) Apoptotic events detected on MAP2-expressing cells as an indication of neuronal death. For (C) & (D), average value determined by counting cells in at least five microscopic fields for each treatment. Results are presented as means ± SEM of four separate experiments. At least four slices from each experimental group observed for each experiment. Statistical analysis performed using parametric one-way analysis of variance, & multiple comparisons performed using Bonferroni test. ***P < 0.001 & *P < 0.05 vs. control; ∘∘P < 0.01 & ∘P < 0.05 vs. A beta -challenge slices. Image collected & cropped by CiteAb from following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-9-49), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-213_chicken-map2-pab-310202416203712.jpg)
![Immunocytochemistry/ Immunofluorescence: MAP2 Antibody [NB300-213] - PEA inhibits astroglial proliferation & reduces neuronal loss in mixed neuroglia co-cultures exposed to A beta . A beta -challenged (1 μg/ml) astrocyte/neuron mixed cultures were treated with PEA (0.1 μM) in the presence of the selective PPAR gamma antagonist (GW9662, 9 nM) or the selective PPAR alpha antagonist (MK886, 3 μM). After 24 hours of treatment, cells were processed for analyses. (A) Immunofluorescence photomicrographs showing the effect of the treatments on astrocyte proliferation & neuronal loss, as determined by immunostaining for GFAP (green) & MAP2 (red), respectively. Arrows indicate chromatin condensation in nuclei stained with Hoechst dye (blue) as markers of apoptotic events. Scale bar: 10 μm. (B) Relative quantification of GFAP-positive cell number as a count of astrocyte proliferation. (C) Apoptotic events detected on MAP2-expressing cells as an indication of neuronal death. For (B) & (C), the average value was determined by counting cells in at least nine microscopic fields for each treatment. Results are presented as means ± SEM of three separate experiments. Statistical analysis was performed using parametric one-way analysis of variance, & multiple comparisons were performed using the Bonferroni test. ***P < 0.001 vs. unstimulated cells, ∘∘P < 0.01 & ∘P < 0.05 vs. A beta -stimulated cultures. Image collected & cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-9-49), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-213_chicken-map2-pab-310202416205136.jpg)
![Analysis of LC3B in HeLa cells using anti-LC3B antibody (red) [Catalog # NB600-1384]. Nuclei were counterstained with DAPI (blue).](http://images.novusbio.com/fullsize/LC3B-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB600-1384-img0033.jpg)
![Analysis of LC3B in treated U87-MG (human glioblastoma astrocytoma) lysates using anti- [Catalog # NB600-1384].](http://images.novusbio.com/fullsize/LC3B-Antibody---BSA-Free-Western-Blot-NB600-1384-img0027.jpg)
![Staining of treated U373-MG (human glioblastoma) cells using anti- [Catalog # NB600-1384].](http://images.novusbio.com/fullsize/LC3B-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB600-1384-img0030.jpg)
![Analysis of U87MG glioma xenografts using anti- [Catalog # NB600-1384]. Image from verified customer review.](http://images.novusbio.com/fullsize/LC3B-Antibody---BSA-Free-Immunohistochemistry-Paraffin-NB600-1384-img0023.jpg)
![Immunocytochemistry/ Immunofluorescence: LC3B Antibody - BSA Free [NB600-1384] - Assesment of functional basal autophagy in vitro(A) Immunoblotting of LC3B & p62 upon pharmacological autophagy inhibition. A dose-dependent increase of LC3B & p62 was observed with increasing concentrations of chloroquine. (B) Immunofluorescence of LC3B & p62 upon pharmacological autophagy inhibition. I. In CC cell lines HT-29 & II. LoVo a dose-dependent increase of LC3B & p62 was observed with increasing concentrations of chloroquine. (C) Electron microscopy of CC cell lines pharmacological autophagy inhibition. I-III. In CC cell line HT-29 a dose-dependent increase of cytoplasmic vesicles was observed with increasing concentrations of CQ. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28903368), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1384_rabbit-polyclonal-lc3b-antibody-310202415384116.jpg)
![Western Blot: LC3B Antibody - BSA Free [NB600-1384] - Phosphorylation of AKT & mTOR decreases after treatment with gemcitabine (GCB)A LM7, CCH-OS-D, & K7M3 osteosarcoma cells were treated with 1μM GCB & cell lysates were analyzed by immunoblotting with specific antibodies for AKT, mTOR, p-AKT, & p-mTOR. beta -actin was used as a loading control. Densitometry was performed using ImageJ. B. & C. Following treatment with GCB, lysates were analyzed using the Human Phospho Kinase Antibody Array. The phosphorylation levels of AKT, mTOR, PRAS40, p70S6K, JNK, AMPK, & ERK were evaluated. Densitometry was performed using Image J. Values were graphed as relative fold change. Means ± standard deviation of three independent experiments are shown. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.20308), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1384_rabbit-polyclonal-lc3b-antibody-310202415304227.jpg)
![Western Blot: LC3B Antibody - BSA Free [NB600-1384] - Autophagy decreases during striatal development. (A) Representative Western blot images for LC3B, p62, DARPP32, & actin. Quantification of (B) LC3B-ii relative to actin, (C) LC3B-ii relative to LC3B-i, (D) p62 relative to actin normalized to P120 values. Data analyzed with one-way ANOVA; (B) Age: F(4,21) = 6.526, p = 0.0014; (C) Age: F(4,22) = 3.797, p = 0.0171; (D) Age: F(4,15) = 3.762, p = 0.0260. *p 0.01); (b) FTC-133/TPC-1 cells transfected with HMGB1 shRNA & control shRNA were starved by HBSS for 3 h & then treated with rapamycin (1 μM) for 12 h. Flow cytometry was performed for measuring the ROS level by a DCFH-DA probe in indicated cells. Rap, rapamycin. (n = 3, *P 0.01); (c) FTC-133/TPC-1 cells were transfected with HMGB1 shRNA & control shRNA & then starved by HBSS for 3 h. ATP levels were detected by ATP Assay Kit (n = 3, *P > 0.01); (d) FTC-133/TPC-1 cells were pretreated with NAC (2 mM) & then starved by HBSS for 3 h. LC3-I/II, NIS, p-AMPK, AMPK, p-mTOR, mTOR, p-p70S6K & p70S6K levels were assayed by Western blot; (e) FTC-133/TPC-1 cells transfected with HMGB1 shRNA & control shRNA were starved by HBSS for 3 h & then treated with rapamycin (1 μM) for 12 h. LC3-I/II, NIS, p-mTOR & mTOR levels were assayed by Western blot. Rap, rapamycin Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31331356), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1384_rabbit-polyclonal-lc3b-antibody-31020241617143.jpg)
![Western Blot: LC3B Antibody - BSA Free [NB600-1384] - Serum starvation induces autophagy & apoptosis in endothelial cells.A Evaluation by Hoechst 33342 & propidium iodide (HO/PI) staining of apoptosis & necrosis in HUVECs exposed to normal medium (N) or serum-starved (SS) for 4 h. P values obtained by unpaired t test. n = 10 for each condition. Scale bar = 25 μm. B Quantification of caspase-3 activity in HUVECs exposed to N or SS HUVECs for 1, 2, 3, & 4 h. P values obtained by one-way ANOVA. n = 4 for each condition. C Immunoblot & densitometric analysis of PARP, LC3, & SQSTM1/p62 in HUVECs exposed to N or SS for 1, 2, or 4 h. beta -actin (ACTB) was used as a loading control. P values obtained by unpaired t test (*P 0.01, **P > 0.01); (d) Dynamic uptaking: FTC-133/TPC-1 cells were transfected with HMGB1 shRNA & control shRNA & starved by HBSS for 3 h. Indicated cells were cultured with 175 KBq 131I for 5, l0, 20, 30, 60, 90 & 120 min. The uptake of 131I in indicated cells was detected by a gamma counter; (e) Radionuclide uptaking: FTC-133/TPC-1 cells were transfected with HMGB1 shRNA & control shRNA in the presence or absence of 3-MA (10 mM) treatment for 1 h & then starved by HBSS for 3 h. After 1-h incubating with 131I, the uptake of 131I in indicated cells was detected by a gamma counter (n = 3, *P 0.01); (f) FTC-133/TPC-1 cells transfected with HMGB1 shRNA & control shRNA were starved by HBSS for 3 h & then treated with rapamycin (1 μM) for 12 h. After 1-h incubating with 131I, the uptake of 131I in indicated cells was detected by a gamma counter. Rap, rapamycin. (n = 3, *P 0.01) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31331356), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1384_rabbit-polyclonal-lc3b-antibody-310202416161815.jpg)
![Western Blot: LC3B Antibody - BSA Free [NB600-1384] - ROS was sufficient for inducing HMGB1 translocation & enhancing autophagy (a) FTC-133/TPC-1 cells were pretreated with the antioxidant (NAC, 2 mM) for 1 h & then starved by HBSS for 3 h. ROS production was assessed by measuring the fluorescent intensity of DCF on a fluorescent plate reader. Incremental production of ROS was expressed as a percentage of control (n = 3, *P 0.01); (b) FTC-133/TPC-1 cells transfected with HMGB1 shRNA & control shRNA were starved by HBSS for 3 h & then treated with rapamycin (1 μM) for 12 h. Flow cytometry was performed for measuring the ROS level by a DCFH-DA probe in indicated cells. Rap, rapamycin. (n = 3, *P 0.01); (c) FTC-133/TPC-1 cells were transfected with HMGB1 shRNA & control shRNA & then starved by HBSS for 3 h. ATP levels were detected by ATP Assay Kit (n = 3, *P > 0.01); (d) FTC-133/TPC-1 cells were pretreated with NAC (2 mM) & then starved by HBSS for 3 h. LC3-I/II, NIS, p-AMPK, AMPK, p-mTOR, mTOR, p-p70S6K & p70S6K levels were assayed by Western blot; (e) FTC-133/TPC-1 cells transfected with HMGB1 shRNA & control shRNA were starved by HBSS for 3 h & then treated with rapamycin (1 μM) for 12 h. LC3-I/II, NIS, p-mTOR & mTOR levels were assayed by Western blot. Rap, rapamycin Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31331356), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1384_rabbit-polyclonal-lc3b-antibody-310202416182641.jpg)
![Western Blot: LC3B Antibody - BSA Free [NB600-1384] - Fucoxanthin activated autophagy after TBI.(A) Representative images of immunofluorescence for LC3 surrounding the injured cortex. LC3 punctate dots were observed in the cytoplasm by immunofluorescent staining of LC3 (red). Neuron cells & nuclei are labeled with NeuN (green) & DAPI (blue), respectively. Magnification: 40 x. Scale bar: 50 mm. (B) Mice brain tissues were collected 1 day after TBI in different groups, & the expression of LC3, Beclin-1 & p62 was measured by western blot. Fucoxanthin treatment significantly increased the level of LC3-II & Beclin-1 while decreasing the level of p62 after TBI. (C) 3-MA (400 nM) was injected i.c.v. 30 min before TBI. Mice were then subjected to TBI & treatment of fucoxanthin 30 min after TBI. Pretreatment with 3-MA significantly attenuated fucoxanthin-induced activation of autophagy & suppression of apoptosis & oxidative stress in the ipsilateral cortex. Data are presented as mean ± SEM, n = 6 per group; **p 0.01, **P > 0.01); (d) Dynamic uptaking: FTC-133/TPC-1 cells were transfected with HMGB1 shRNA & control shRNA & starved by HBSS for 3 h. Indicated cells were cultured with 175 KBq 131I for 5, l0, 20, 30, 60, 90 & 120 min. The uptake of 131I in indicated cells was detected by a gamma counter; (e) Radionuclide uptaking: FTC-133/TPC-1 cells were transfected with HMGB1 shRNA & control shRNA in the presence or absence of 3-MA (10 mM) treatment for 1 h & then starved by HBSS for 3 h. After 1-h incubating with 131I, the uptake of 131I in indicated cells was detected by a gamma counter (n = 3, *P 0.01); (f) FTC-133/TPC-1 cells transfected with HMGB1 shRNA & control shRNA were starved by HBSS for 3 h & then treated with rapamycin (1 μM) for 12 h. After 1-h incubating with 131I, the uptake of 131I in indicated cells was detected by a gamma counter. Rap, rapamycin. (n = 3, *P 0.01) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31331356), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1384_rabbit-polyclonal-lc3b-antibody-31020241616376.jpg)
![Western Blot: LC3B Antibody - BSA Free [NB600-1384] - Metformin treatment increases cisplatin effects; (A) MDA-MB-231 & Ca Ski cells were either left untreated or treated with metformin or cisplatin alone or metformin in combination with cisplatin for 15 days. At the end of the treatment, cells were processed to obtain whole cell lysates. MAP1LC3B, pPRKAA2Thr172, PRKAA2 & CASP3 (cleaved) expression was determined by Western blot. ACTB was used as loading control. Densitometric analysis of the gels was performed as described under Materials & Methods; (B) MDA-MB-231 & Ca Ski cells were either left untreated or treated with metformin or cisplatin alone or metformin in combination with cisplatin for 15 days. Ammonia level in the culture medium was measured as indicated in the Material & Methods section. # Significantly different from treatment with metformin alone. All experiments in this figure were repeated three times. * Significantly different from control untreated cells. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30646605), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1384_rabbit-polyclonal-lc3b-antibody-31020241618938.jpg)
![Western Blot: LC3B Antibody - BSA Free [NB600-1384] - Autophagy & the proteasome regulate CagA stability. (A) Wild-type (WT) & autophagy-deficient (Atg5−/−) MEFs were infected with a CagA+ vacA− isogenic mutant strain (MOI 100) for 8 hours using a gentamycin protection assay. The autophagy marker LC3-II was used to confirm that Atg5−/− MEFs are autophagy-deficient. CagA protein levels were measured by Western blotting using beta -actin as loading control. Graph shows fold change of CagA normalized to beta -actin relative to WT MEFs (mean + SEM; n = 4). (B) AGS cells were infected with a CagA+ vacA− isogenic mutant strain (MOI 50) for 19 hours using a gentamycin protection assay. MG132 (5 μM) was added during the 14-hour low-dose gentamycin incubation. DMSO was used as a vehicle control. CagA protein levels were measured by Western blotting using beta -actin as loading control. Graph shows fold change of CagA normalized to beta -actin relative to vehicle control (mean + SEM; n = 6). (C) AGS cells were infected with a CagA+ vacA− isogenic mutant strain (MOI 50) for 24 hours using a gentamycin protection assay. Lactacystin (10 μM) was added during the 19-hour low-dose gentamycin incubation. Water was used as a vehicle control. CagA protein levels were measured by Western blotting using beta -actin as loading control. Graph shows fold change of CagA normalized to beta -actin relative to vehicle control (mean + SEM; n = 5). Relevant gel bands were cropped from the original blots. Dotted line indicates slicing of two regions together from the same blot. Statistical analysis was performed using Student’s t-test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30631092), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1384_rabbit-polyclonal-lc3b-antibody-310202416173533.jpg)
![Western Blot: LC3B Antibody - BSA Free [NB600-1384] - Vps34 activity is required for maintaining LC3B-ii levels at P10 & mTOR inhibition increases p-Beclin-1 & LC3B-ii levels at P28. (A) Representative Western blot images for actin, DARPP32 & LC3B-i & -ii in striatal slices obtained from P10 or P28 mice, treated with SAR405 (1 μM) or vehicle (Veh; DMSO, 0.1%). (B,C) Quantification of LC3B-ii relative to actin, normalized to vehicle condition at each age. (B) P10: unpaired, two-tailed t-test, t11 = 2.985, p = 0.0124; P28: unpaired, two-tailed t-test, t24 = 1.807, p = 0.0922. P10: Veh: n = 6 slices, SAR405 n = 7 slices from 3 to 4 mice/age. (C) P28: Veh: n = 9 slices, Baf n = 7 slices from 3 to 4 mice/age. *p 0.05 versus untreated group). C. Morphological features of NB4 cells that were treated with ATRA (1 μM) or HMGB1 (1 μg/ml) was determined by Wright-Giemsa staining & visualized by light microscopy (100X magnification). D. Differentiation of NB4 cells treated with ATRA (1 μM) or HMGB1 (10 μg/ml) for 6-48 h was examined by NBT reduction & surface CD11b expression in comparison to the control (DMSO) (n=3, *P<0.05 versus ATRA group). E. Expression of PML-RAR alpha , P62 & LC3-I/II in NB4 cells treated with ATRA (1 μM) or HMGB1 (10 μg/ml) for 48 h was assayed by western blotting & co-immunoprecipitation in comparison to control (DMSO). Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.15432), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1384_rabbit-polyclonal-lc3b-antibody-310202416171499.jpg)
![Western Blot: LC3B Antibody - BSA Free [NB600-1384] - Zearalenone (ZEN) induced endoplasmic reticulum (ER) stress & autophagy in HepG2 cells. mRNA level & protein expression were determined by quantitative real-time polymerase chain reaction (qRT-PCR) & Western blot analysis, respectively. (A) The protein expression level of GRP78 was measured in cells treated with ZEN for 1 h. (B) The phosphorylation of eIF2 alpha was evaluated in cells treated with ZEN for 2 h. (C) CHOP mRNA levels, (D) Beclin1 mRNA levels, & (E) LC3-II mRNA levels were determined in cells treated with ZEN for 4 h. (F) The protein expression level of LC3-II/LC3-I was examined in cells treated with ZEN for 24 h. Data represent mean ± SEM of three independent experiments. * indicates significant difference vs. the control (** p < 0.01, & *** p < 0.001). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31861425), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1384_rabbit-polyclonal-lc3b-antibody-310202416154612.jpg)
![Western Blot: LC3B Antibody - BSA Free [NB600-1384] - ATRA induces autophagy in SKBR3 cells. (a) SKBR3 & MDA-MB-453 breast cancer cells were treated either with 0.1 or 1 μM ATRA for 2 & 4 days, respectively. beta -Catenin & LC3B levels were measured by western blotting. GAPDH was used as a loading control. (b) LC3B-II quantification from at least three independent experiments. LC3B-II expression was normalized to GAPDH & to vehicle-treated SKBR3 cells. (c) beta -Catenin staining of SKBR3 & MDA-MB453 cells. Cells were control or ATRA (1 μM) treated for 2 days. beta -Catenin FITC (fluorescein isothiocyanate) & nuclear DAPI (4',6-diamidino-2-phenylindole) staining as analyzed by confocal microscopy are shown. (d) Quantification of endogenous LC3B puncta. LC3B in SKBR3 & MDA-MB453 cells treated with 1 μM ATRA for 2 days. (e) LC3B-II western blotting & quantification of the autophagic activation upon treatment with 1 μM ATRA for 2 days in the presence or absence of BafA for 2 h at 200 nM. LC3B-II levels were normalized to GAPDH & to vehicle-treated SKBR3 cells. Standard deviations for five independent experiments are shown. (f) Long-lived protein degradation assay of SKBR3 & MDA-MB453 cells treated as in (e). Radioactivity was determined by liquid scintillation counting of at least three independent experiments. Absolute proteolysis is shown. (g) Long-lived protein degradation assay of SKBR3 treated as in (e) & including treatment with the macroautophagy-specific inhibitor 3-MA (10 mM). Analysis as in (f). Mann–Whitney U-test: *P<0.05, **P<0.01, ***P<0.001 & ****P<0.0001 Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/cddis2015236), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1384_rabbit-polyclonal-lc3b-antibody-31020241616052.jpg)
![Western Blot: LC3B Antibody - BSA Free [NB600-1384] - CA1 Tg mice undergo mitochondrial stress. a WB analysis of extracts from 6-mo Wt & Tg mice CA1 (Wt, n = 6; Tg, n = 7), using antibodies against SIRT3, SOD2 & acetylated SOD2. b WB analysis of extracts from 12-mo Wt & Tg mice hippocampi (Wt, n = 5; Tg, n = 5). Data are presented as mean ± SEM (**P < 0.01; ***P < 0.001). WB analysis of extracts from 6-mo Wt & Tg mice CA1 (Wt, n = 6; Tg, n = 5) (c), & from 12-mo Wt & Tg mice hippocampi (Wt, n = 5; Tg, n = 5) (d) for PINK1 & LC-3. Data are presented as mean ± SEM, *P < 0.05. WB analysis of extracts from 6-mo WT & Tg mice CA1 (WT, n = 5; Tg, n = 6) (e), & from 12-mo WT & Tg mice hippocampi (WT, n = 5; Tg, n = 5) (f) for TFAM. Data are presented as mean ± SEM (*P < 0.05), **P < 0.01). Actin was used as loading control Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32131898), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1384_rabbit-polyclonal-lc3b-antibody-31020241616181.jpg)
![Western Blot: LC3B Antibody - BSA Free [NB600-1384] - ATRA induces autophagy in SKBR3 cells. (a) SKBR3 & MDA-MB-453 breast cancer cells were treated either with 0.1 or 1 μM ATRA for 2 & 4 days, respectively. beta -Catenin & LC3B levels were measured by western blotting. GAPDH was used as a loading control. (b) LC3B-II quantification from at least three independent experiments. LC3B-II expression was normalized to GAPDH & to vehicle-treated SKBR3 cells. (c) beta -Catenin staining of SKBR3 & MDA-MB453 cells. Cells were control or ATRA (1 μM) treated for 2 days. beta -Catenin FITC (fluorescein isothiocyanate) & nuclear DAPI (4',6-diamidino-2-phenylindole) staining as analyzed by confocal microscopy are shown. (d) Quantification of endogenous LC3B puncta. LC3B in SKBR3 & MDA-MB453 cells treated with 1 μM ATRA for 2 days. (e) LC3B-II western blotting & quantification of the autophagic activation upon treatment with 1 μM ATRA for 2 days in the presence or absence of BafA for 2 h at 200 nM. LC3B-II levels were normalized to GAPDH & to vehicle-treated SKBR3 cells. Standard deviations for five independent experiments are shown. (f) Long-lived protein degradation assay of SKBR3 & MDA-MB453 cells treated as in (e). Radioactivity was determined by liquid scintillation counting of at least three independent experiments. Absolute proteolysis is shown. (g) Long-lived protein degradation assay of SKBR3 treated as in (e) & including treatment with the macroautophagy-specific inhibitor 3-MA (10 mM). Analysis as in (f). Mann–Whitney U-test: *P<0.05, **P<0.01, ***P<0.001 & ****P<0.0001 Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/cddis2015236), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1384_rabbit-polyclonal-lc3b-antibody-310202416182623.jpg)
![Western Blot: LC3B Antibody - BSA Free [NB600-1384] - Bmi‐1 deficiency aggravates cardiac hypertrophy & decreases autophagic flux. (A) Representative micrographs of paraffin‐embedded heart ventricular wall sections of 6‐week‐old Bmi‐1–/– mice & WT mice stained for haematoxylin‐eosin (H&E), wheat germ agglutinin (WGA) & Masson's trichrome (Masson) staining. (B) Heart weight relative to body weight (HW/BW) & heart weight relative to tibia length (HW/TL). (C) The wall thickness of interventricular septum. (D) Myocyte cross‐sectional area from Bmi‐1–/– mice relative to WT mice. (E) Collagenous fibre area from Bmi‐1–/– mice relative to WT mice was counted with anterior wall staining for Masson. (F) Anp, Bnp, beta ‐MHC, c‐TnI & GATA4 mRNA levels in hearts by real‐time RT‐PCR, calculated as ratio to beta ‐actin mRNA & expressed relative to WT. (G) Western blots of cardiac tissue extracts & mouse embryonic cardiomyocytes (MECs) showing ANP, BNP, GATA4, LC3B & p16; beta ‐actin was the loading control. (H) Protein levels relative to beta ‐actin were assessed by densitometric analysis. (I) Representative micrographs of paraffin‐embedded heart sections immunohistochemical staining for ANP, BNP & GATA4. (J) The percentage of cells positive for ANP, BNP, GATA4 or positive area relative to total cells or area. (K) Representative micrographs of fluorescence with autophagy lentivirus transfection, with DAPI for nuclei. (L) Percentage of positive GFP dots or mRFP dots relative to total cells. (M) The number of autophagosomes & autolysosomes per cell. Six mice per group were used for experiments. Cell experiments were performed with three biological repetitions per group. Values are mean ± SEM from six determinations per group, *p < .05, **p < .01, ***p < .001 compared with WT group, unpaired Student's t‐test Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35390228), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1384_rabbit-polyclonal-lc3b-antibody-31020241618262.jpg)
![Western Blot: LC3B Antibody - BSA Free [NB600-1384] - 8-Cl-Ado-induces autophagy. Immunoblot analysis of (A) phospho-ULK (Ser555) levels & (B) LC3B-I lipidation to form LC3B-II in MCF-7 & BT-474 cells treated with 10 μM of 8-Cl-Ado for the indicated times. (C) Fluorescent microscopy of MCF-7 & BT-474 cells transiently transfected with GFP-LC3B & treated with 10 μM of 8-Cl-Ado for 12-hours to assess aggregation of LC3B. (D) Immunoblot analysis of p62 levels in MCF-7 & BT-474 cells treated with 10 μM of 8-Cl-Ado for the indicated times. The normalized ratio of p62 to GAPDH relative to the untreated control is indicated beneath each lane. (E) Fluorescent microscopic imaging of autolysosomes. MCF-7 cells were untreated or treated for 2-days with 8-Cl-Ado or rapamycin. Cells were stained with MDC, blue, to visualize AVO & Syto 61 (DNA), red, for nuclei counterstaining. (F) Representative flow cytometery histograms of AVO stained with acridine orange in MCF-7 cells untreated or treated for 3 days with 50 nM rapamycin or 10 μM 8-Cl-Ado. Baf was added before 30 min prior to staining to neutralize AVO staining. (G) Quantification triplicate experiments of MCF-7 & BT-474 cells treated & analyzed as in E. Image collected & cropped by CiteAb from the following publication (//jhoonline.biomedcentral.com/articles/10.1186/1756-8722-7-23), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1384_rabbit-polyclonal-lc3b-antibody-31020241617525.jpg)
![Western Blot: LC3B Antibody - BSA Free [NB600-1384] - PB induces autophagy but blocks autophagosome trafficking & autophagosome-lysosome fusion in Hep3B cells.(A) Hep3B cells, HepG2 cells, & primary mouse hepatocytes treated w/ increasing concentrations of PB (6–2000 μg/mL) for 24 h; viable cells quantified using the MTT assay. Data are presented as mean ± SD from at least 3 independent experiments. Bars = SD. *P < 0.05, **P < 0.01, ***P < 0.001, control versus PB-treated cells. (B) Hep3B cells treated for 6, 24 & 48 h w/ indicated concentrations of PB. Levels of protein expression analysed by WB using antibodies against LC3B, p62/SQSTM1, ATG12, BECN1 & Actin. Images cropped from different blots run under the same experimental conditions. The original blots attached as Supplementary Figure 3A. (C) Hep3B cells transfected w/ GFP-LC3B treated w/ 240 μg/mL PB for 24 h & then observed under a confocal microscope. (D) Hep3B cells treated for 24 h w/ indicated concentrations of PB. Levels of protein expression analysed by WB using antibodies against phosphorylated & total mTOR, 4EBP1, & p70S6K1 as well as actin. Images cropped from different blots run under the same experimental conditions. The original blots attached as Supplementary Figure 3B. (E) Hep3B cells serum-starved overnight, & incubated w/ or w/out PB (240 μg/mL) for 6 h before stimulating w/ 20 ng/mL EGF for 20 min. EGFR protein levels analysed by confocal microscope. (F) Hep3B cells treated PB for 12, 24 or 48 h w/ indicated concentrations. Levels of protein expression analysed by WB using antibodies against EGFR & Actin. Images cropped from different blots run under the same experimental conditions in each panel. The original blots attached as Supplementary Figure 3C. Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/srep41437), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1384_rabbit-polyclonal-lc3b-antibody-31020241618948.jpg)
![Immunocytochemistry/Immunofluorescence: MAP2 Antibody (4H5) [NBP2-25156] - Mixed neuron and glia cultures stained with NBP2-25156 (green), and NB300-135 rabbit antibody to NF-H (red) and DNA (blue). NBP2-25156 reveals strong cytoplasmic staining for of dendrites and perikarya, which does not overlap with the NF-H antibody, which primarily binds to axons.](http://images.novusbio.com/fullsize/MAP2-Antibody-4H5-Immunocytochemistry-Immunofluorescence-NBP2-25156-img0003.jpg "Immunocytochemistry/Immunofluorescence: MAP2 Antibody (4H5) [NBP2-25156] - Mixed neuron and glia cultures stained with NBP2-25156 (green), and NB300-135 rabbit antibody to NF-H (red) and DNA (blue). NBP2-25156 reveals strong cytoplasmic staining for of dendrites and perikarya, which does not overlap with the NF-H antibody, which primarily binds to axons.")
![Immunohistochemistry Free-Floating: MAP2 Antibody (4H5) [NBP2-25156] - Analysis of a rat hippocampus section stained with mouse mAb to MAP2, NBP2-25156, dilution 1:2,000 in green, and costained with rabbit pAb to FOX3/NeuN, dilution 1:2,000 in red. Following transcardial perfusion of rat with 4% paraformaldehyde, brain was post fixed for 24 hours, cut to 45uM, and free-floating sections were stained with above antibodies. The NBP2-25156 antibody labels MAP2 protein in the perikarya and dendrites of most neurons while the FOX3/NeuN antibody selectively stains nuclei and proximal soma of neuronal cells.](http://images.novusbio.com/fullsize/MAP2-Antibody-4H5-Immunocytochemistry-Immunofluorescence-NBP2-25156-img0005.jpg)
![Western Blot: MAP2 Antibody (4H5) [NBP2-25156] - Analysis of tissue and cell lysates using mouse mAb to MAP2, NBP2-25156, dilution 1:10,000 in green: [1] protein standard (red), [2] rat brain, [3] mouse brain, and [4] embryonic rat cortical neuron-glial cell lysate. A band at about 280 kDa corresponds to the MAP2A and MAP2B proteins.](http://images.novusbio.com/fullsize/MAP2-Antibody-4H5-Western-Blot-NBP2-25156-img0006.jpg)
![Immunohistochemistry-Paraffin: MAP2 Antibody (4H5) [NBP2-25156] - Analysis of MAP2 in a 1% PFA fixed mouse brain section using anti-MAP2 (red) and NeuN (green) antibodies. Image from verified customer review.](http://images.novusbio.com/fullsize/MAP2-Antibody-4H5-Immunohistochemistry-Paraffin-NBP2-25156-img0004.jpg)
![Immunohistochemistry-Paraffin: MAP2 Antibody (4H5) [NBP2-25156] - Staining in mouse brain. Image from a verified customer review.](http://images.novusbio.com/fullsize/MAP2-Antibody-4H5-Immunohistochemistry-Paraffin-NBP2-25156-img0008.jpg)
![Immunohistochemistry-Paraffin: MAP2 Antibody (4H5) [NBP2-25156] - Staining of a 1% PFA fixed mouse cortical region section with anti-MAP 2 (dilution 1:300; Alexa 568 red). Image from a verified customer review.](http://images.novusbio.com/fullsize/MAP2-Antibody-4H5-Immunohistochemistry-Paraffin-NBP2-25156-img0007.jpg)
![Immunohistochemistry Free-Floating: MAP2 Antibody (5H11) [NBP1-92711] - Analysis of rat hippocampus section stained with mouse mAb to MAP2, NBP1-92711, dilution 1:5,000 in green, and costained with rabbit pAb to alpha-internexin, dilution 1:2,000 in red. Following transcardial perfusion of rat with 4% paraformaldehyde, brain was post fixed for 24 hours, cut to 45uM, and free-floating sections were stained with above antibodies. The NBP1-92711 antibody labels MAP2 protein in the perikarya and dendrites of the most neurons, and the alpha-internexin antibody selectively stains axons and dendrites of neuronal cells.](http://images.novusbio.com/fullsize/MAP2-Antibody-5H11-Immunocytochemistry-Immunofluorescence-NBP1-92711-img0001.jpg "Immunohistochemistry Free-Floating: MAP2 Antibody (5H11) [NBP1-92711] - Analysis of rat hippocampus section stained with mouse mAb to MAP2, NBP1-92711, dilution 1:5,000 in green, and costained with rabbit pAb to alpha-internexin, dilution 1:2,000 in red. Following transcardial perfusion of rat with 4% paraformaldehyde, brain was post fixed for 24 hours, cut to 45uM, and free-floating sections were stained with above antibodies. The NBP1-92711 antibody labels MAP2 protein in the perikarya and dendrites of the most neurons, and the alpha-internexin antibody selectively stains axons and dendrites of neuronal cells.")
![Western Blot: MAP2 Antibody (5H11) [NBP1-92711] - Analysis of different tissue lysates using mouse mAb to MAP2A/B (5H11), NBP1-92711, dilution 1:10,000 in green: [1] protein standard (red), [2] adult rat whole brain, [2] embryonic (E20) rat brain, [4] adult rat spinal cord, and [5] adult mouse brain lysate. A band observed at about 280 kDa corresponds to full length MAP2a and MAP2B protein. MAP2A/B is expressed heavily in brain particularly in cortical regions, but is a more minor component of spinal cord. Note that the epitope for this antibody in within the projection domain, and so the antibody does not bind to the lower molecular weight MAP2C and MAP2D isoforms which lack this region.](http://images.novusbio.com/fullsize/MAP2-Antibody-5H11-Western-Blot-NBP1-92711-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: MAP2 Antibody (5H11) [NBP1-92711] - Single cultured astrocytes stained with MAP2 (red) and Myelin (green). Image from a verified customer review.](http://images.novusbio.com/fullsize/MAP2-Antibody-5H11-Immunocytochemistry-Immunofluorescence-NBP1-92711-img0003.jpg)
![Western Blot: MAP2 Antibody (CL5420) [NBP2-61417] - Analysis in human cell line SH-SY5Y. Observed molecular weight 89 and 280 kDA.](http://images.novusbio.com/fullsize/MAP2-Antibody-CL5420-Western-Blot-NBP2-61417-img0007.jpg "Western Blot: MAP2 Antibody (CL5420) [NBP2-61417] - Analysis in human cell line SH-SY5Y. Observed molecular weight 89 and 280 kDA.")
![Immunocytochemistry/Immunofluorescence: MAP2 Antibody (CL5420) [NBP2-61417] - Staining of SH-SY5Y cells using the Anti-MAP2 monoclonal antibody, showing specific staining in the cytosol and in microtubules in green. Microtubule and nuclear probes are visualized in red and blue, respectively (where available). Antibody staining is shown in green.](http://images.novusbio.com/fullsize/MAP2-Antibody-CL5420-Immunocytochemistry-Immunofluorescence-NBP2-61417-img0002.jpg)
![Immunohistochemistry-Paraffin: MAP2 Antibody (CL5420) [NBP2-61417] - Staining of human tonsil shows absence of positivity in lymphoid cells as expected (negative control).](http://images.novusbio.com/fullsize/MAP2-Antibody-CL5420-Immunohistochemistry-Paraffin-NBP2-61417-img0006.jpg)
![Immunohistochemistry-Paraffin: MAP2 Antibody (CL5420) [NBP2-61417] - Staining of human cerebral cortex shows cytoplasmic immunoreactivity in neurons, as well as positivity in neuropil.](http://images.novusbio.com/fullsize/MAP2-Antibody-CL5420-Immunohistochemistry-Paraffin-NBP2-61417-img0003.jpg)
![Immunohistochemistry-Paraffin: MAP2 Antibody (CL5420) [NBP2-61417] - Staining of human cerebellum shows positivity in a subset of neurons.](http://images.novusbio.com/fullsize/MAP2-Antibody-CL5420-Immunohistochemistry-Paraffin-NBP2-61417-img0004.jpg)
![Immunohistochemistry-Paraffin: MAP2 Antibody (CL5420) [NBP2-61417] - Staining of human pancreas shows cytoplasmic immunoreactivity in pancreatic islets.](http://images.novusbio.com/fullsize/MAP2-Antibody-CL5420-Immunohistochemistry-Paraffin-NBP2-61417-img0005.jpg)
![Western Blot: MAP2 Antibody [NBP3-05552] - Western blot analysis of whole brain lysates using MAP2 Antibody at a dilution of 1:5,000 in green: [1] protein standard (red), [2] rat, and [3] mouse brain lysate. A band at about 280kDa corresponds to the MAP2A and MAP2B proteins.](http://images.novusbio.com/fullsize/MAP2-Antibody-Western-Blot-NBP3-05552-img0002.jpg "Western Blot: MAP2 Antibody [NBP3-05552] - Western blot analysis of whole brain lysates using MAP2 Antibody at a dilution of 1:5,000 in green: [1] protein standard (red), [2] rat, and [3] mouse brain lysate. A band at about 280kDa corresponds to the MAP2A and MAP2B proteins.")
![Immunocytochemistry/Immunofluorescence: MAP2 Antibody [NBP3-05552] - Immunofluorescent analysis of rat brain stem section stained with goat pAb to MAP2 at a dilution of 1:2,000 in red, and costained with mouse mAb to MBP at a dilution of 1:5,000, in green. Following transcardial perfusion of rat with 4% paraformaldehyde, brain was post fixed for 24 hours, cut to 45uM, and free-floating sections were stained with above antibodies. MAP2 Antibody labels MAP2 protein in the perikarya and dendrites of the most neurons, notably motorneurons in the brain stem, and the MBP antibody stains myelin sheath around axons.](http://images.novusbio.com/fullsize/MAP2-Antibody-Immunocytochemistry-Immunofluorescence-NBP3-05552-img0001.jpg)
![Immunocytochemistry/Immunofluorescence: MAP2 Antibody [NBP1-81263] - Staining of human cell line A-431 shows localization to nucleoli & cytosol.](http://images.novusbio.com/fullsize/MAP2-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-81263-img0001.jpg "Immunocytochemistry/Immunofluorescence: MAP2 Antibody [NBP1-81263] - Staining of human cell line A-431 shows localization to nucleoli & cytosol.")
![Immunohistochemistry-Paraffin: MAP2 Antibody (HL1656) - Azide and BSA Free [NBP3-25555] - MAP2 antibody [HL1656] detects MAP2 protein at cell membrane and cytoplasm by immunohistochemical analysis. Sample: Paraffin-embedded rat brain. MAP2 stained by MAP2 antibody [HL1656] (NBP3-25555) diluted at 1:100. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp3-25555_rabbit-map2-mab-hl1656-azide-and-bsa-free-212024939165.jpg "Immunohistochemistry-Paraffin: MAP2 Antibody (HL1656) - Azide and BSA Free [NBP3-25555] - MAP2 antibody [HL1656] detects MAP2 protein at cell membrane and cytoplasm by immunohistochemical analysis. Sample: Paraffin-embedded rat brain. MAP2 stained by MAP2 antibody [HL1656] (NBP3-25555) diluted at 1:100. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min")
![Immunocytochemistry/Immunofluorescence: MAP2 Antibody (HL1656) - Azide and BSA Free [NBP3-25555] - MAP2 antibody [HL1656] detects MAP2 protein in dendrites, but not in axons, by immunofluorescent analysis. Sample: DIV9 rat E18 primary hippocampal neuron cells were fixed in 4% paraformaldehyde at RT for 15 min. Green: MAP2 stained by MAP2 antibody [HL1656] (NBP3-25555) diluted at 1:250. Red: Tau, an axon marker, stained by Tau antibody [GT287] diluted at 1:500. Blue: Fluoroshield with DAPI .](http://images.novusbio.com/fullsize/nbp3-25555_rabbit-map2-mab-hl1656-azide-and-bsa-free-212024941460.jpg)
![Immunohistochemistry-Paraffin: MAP2 Antibody (HL1656) - Azide and BSA Free [NBP3-25555] - MAP2 antibody [HL1656] detects MAP2 protein at cell membrane and cytoplasm by immunohistochemical analysis. Sample: Paraffin-embedded mouse brain. MAP2 stained by MAP2 antibody [HL1656] (NBP3-25555) diluted at 1:100. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp3-25555_rabbit-map2-mab-hl1656-azide-and-bsa-free-2120249413331.jpg)
![Immunocytochemistry/Immunofluorescence: MAP2 Antibody [NB100-98717] - Rat brain at 1:500 dilution using Sheep antibody to rat, mouse Mtap2 whole serum DAPI counterstained appearing in blue.](http://images.novusbio.com/fullsize/MAP2-Antibody-Immunocytochemistry-Immunofluorescence-NB100-98717-img0003.jpg "Immunocytochemistry/Immunofluorescence: MAP2 Antibody [NB100-98717] - Rat brain at 1:500 dilution using Sheep antibody to rat, mouse Mtap2 whole serum DAPI counterstained appearing in blue.")
![ELISA: Human MAP2 ELISA Kit (Colorimetric) [NBP2-80250] - Samples were spiked with high concentrations of Human MAP2 and diluted with Reference Standard & Sample Diluent to produce samples with values within the range of the assay.](http://images.novusbio.com/fullsize/nbp2-80250_human-map2-elisa-kit-colorimetric-132202416201952.jpg "ELISA: Human MAP2 ELISA Kit (Colorimetric) [NBP2-80250] - Samples were spiked with high concentrations of Human MAP2 and diluted with Reference Standard & Sample Diluent to produce samples with values within the range of the assay.")
![ELISA: Human MAP2 ELISA Kit (Colorimetric) [NBP2-80250] - Standard Curve Reference](http://images.novusbio.com/fullsize/nbp2-80250_human-map2-elisa-kit-colorimetric-432024915865.jpg)